Vertex moves to buy Crinetics in $10 billion endocrinology deal | iPharmaCenter

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in an all‑cash transaction that values the endocrine specialist at about $10 dollars.

Under the terms of the definitive agreement, Vertex will pay $85 per Crinetics share, with the deal valued at roughly $8.8 billion net of cash on hand, and closing targeted for the third quarter of 2026 subject to regulatory and shareholder approvals.

Also read: CVS Pharmacy Joins Medicare GLP-1 Bridge and Scales Weight‑Loss Access Across the U.S

Palsonify: once‑daily oral option in acromegaly

Crinetics’ lead commercial asset is Palsonify (paltusotine), a once-daily oral somatostatin receptor agonist for adults with acromegaly. The drug, approved by the US Food and Drug Administration in September 2025 and recently cleared by the European Medicines Agency, offers an alternative to injectable somatostatin analogues for patients who either did not achieve adequate control with surgery or are not candidates for surgical intervention.

Clinical data show that paltusotine can reduce growth hormone and IGF‑1 levels and bring key disease markers into the normal range in both treatment‑experienced and treatment‑naive populations. Since launch, Palsonify has seen encouraging uptake, with growth across patient segments, expanding prescribing by endocrinologists and improving reimbursement coverage, positioning it to reshape expectations around convenience and symptom control in acromegaly management.

Also read: Medicare GLP‑1 Bridge Program: Eligibility, Costs, and Drug Details

Atumelnant: Phase 3 ACTH antagonist in CAH

The most advanced pipeline candidate Vertex will acquire is atumelnant, a once‑daily oral antagonist of the ACTH receptor (MC2R) in Phase 3 development for classical congenital adrenal hyperplasia. Classic CAH is a severe inherited disorder of cortisol synthesis that leads to chronic ACTH elevation and excess androgen production, with around 17,000 addressable patients in the United States and significant unmet need despite long‑standing steroid‑based regimens.

In Phase 2 studies, atumelnant has shown the ability to rapidly and sustainably lower adrenal androgen levels while allowing patients to remain on physiologic replacement doses of glucocorticoids, rather than the supraphysiologic doses often required with current approaches. That therapeutic profile aligns closely with the clinical goal in CAH and has led Crinetics to position atumelnant as a potential leading medical therapy for the condition. Across dose ranges, the drug has been generally well tolerated, with no treatment‑related severe or serious adverse events reported and a safety profile characterised mainly by mild to moderate headaches and fatigue.

Also read: Top 10 Pharma Companies by Revenue in 2025

Strategic fit for Vertex

By bringing in Palsonify and atumelnant, Vertex adds a commercial rare-endocrine product and a late-stage ACTH antagonist that could both contribute to long-term growth outside cystic fibrosis. The company has indicated that, at peak, the two programmes together could generate more than $5 billion in annual revenue, supporting its aim of sustained growth and high operating margins.